
Nova Eye Completes \$8m Placement

Highlights

- **Firm Commitments received for A\$8m share placement at A\$0.18 per share**

Nova Eye Medical Limited (ASX: **EYE**) (**Nova Eye Medical** or the **Company**), is pleased to announce it has raised A\$8 million (before costs) from sophisticated and other professional investors through a Share Placement (Placement). The Placement was strongly supported by existing and new institutional investors. Directors of the Company have committed to subscribe for A\$270,000 (subject to shareholder approval).

Capital Raising Details

Nova Eye Medical has received binding commitments for a Placement by way of a two-tranche structure of 44.4 million new fully paid ordinary shares (**Securities**) to institutional, sophisticated and professional investors (**the Offer**).

The first tranche will be issued in accordance with the Company's available placement capacity pursuant to ASX Listing Rule 7.1 and will be a total of 21,004,542 Securities (3.78 million).

The second tranche will see the remaining 23,439,902 Securities (\$4.22m) issued subject to approval from shareholders, at a General Meeting expected to be held in April 2023.

The Placement was conducted by Taylor Collison Limited, E&P Corporate Advisory Pty Ltd and MST Financial Services Pty Ltd as joint lead managers. Settlement of the Placement is expected to occur on Tuesday 7 March 2023, with first tranche shares expected to be allotted and to commence trading on Wednesday 8 March 2023. The total capital raising fee was 6%.

The Capital Raising price of A\$0.18 (18 cents) per New Share represents a discount of 21.7% to the last traded price on 24 February 2023.

Proceeds from the Placement will be used principally to fund the expansion of the Company's Glaucoma Surgical Devices in the USA, Europe and China.

Authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited

– ENDS –

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Kate Hunt
Chief Commercial Officer
+61 404 080 679
khunt@nova-eye.com

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL LIMITED

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.
